Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2
Institute of Infection and Immunity · McGill University Health Centre · +9 more institutions
Abstract
Diagnostic testing to identify persons infected with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection is central to control the global pandemic of COVID-19 that began in late 2019. In a few countries, the use of diagnostic testing on a massive scale has been a cornerstone of successful containment strategies. In contrast, the United States, hampered by limited testing capacity, has prioritized testing for specific groups of persons. Real-time reverse transcriptase polymerase chain reaction-based assays performed in a laboratory on respiratory specimens are the reference standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly…
Citation impact
- FWCI
- 15.39
- Percentile
- 100%
- References
- 56
Authors
8- MPMatthew P. ChengCorresponding
Institute of Infection and Immunity, McGill University Health Centre
- JPJesse Papenburg
Montreal Children's Hospital
- MDMichaël Desjardins
Brigham and Women's Hospital, Centre Hospitalier de l’Université de Montréal
- SKSanjat Kanjilal
Harvard University, Harvard Pilgrim Health Care, Brigham and Women's Hospital
- CQCaroline Quach
Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal
Topics & keywords
- Medicine
- Intensive care medicine
- Pandemic
- Point-of-care testing
- Coronavirus
- Diagnostic test
- Convalescence
- Immunology